Literature DB >> 26101370

Is surgery necessary for 'mild' or 'asymptomatic' hyperparathyroidism?

Bruno Niederle1, Jean-Louis Wémeau2.   

Abstract

A large majority of the currently diagnosed patients with hyperparathyroidism (PHPT) are mild or asymptomatic, mainly women after menopause. Following the debate held at the 16th European Congress of Endocrinology in Wroclaw (Poland) from May 3-7, 2014, arguments are here presented by a surgeon and a medical practitioner considering these situations rather have to profit from surgery, or simply from survey. For the trained endocrine surgeon, it is evident that parathyroidectomy confirms the diagnosis and undoubtedly reduces the discomfort felt by certain patients, prevents all risks of complications, removes patients and medical teams from the monitoring and represents a real individual financial benefit. On the other hand, the medical practitioner considers that mild or asymptomatic PHPT is commonly stable, and very rare are the subjects at risk of complications, particularly of fractures; prevention of vascular and metabolic disorders, nephrolithiasis and bone rarefaction justify regular physical exercise, a safe alimentation, a sufficient calcium and high water intake, the correction of the frequent deficit in vitamin D; finally has also to be considered the impossibility to refer to specialized (endocrine) surgeons, the enormous cohort of subjects more than 50 years with 'mild' or 'asymptomatic' PHPT. The surgeon and the medical practitioner agree to consider that in patients with 'mild' or 'asymptomatic' disease, there is no place for medical treatments, in particular calcimimetics and bisphophonates. Both agree that further studies are needed to clarify the long-term prognosis of operated and non-operated PHPT in term of fractures, cardiovascular risk and mortality. Individual and collective cost/benefit ratios of surgery or survey are also still imperfectly evaluated.
© 2015 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26101370     DOI: 10.1530/EJE-15-0277

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  7 in total

1.  Resolution of hypercalcemia in primary hyperparathyroidism with vitamin D replacement.

Authors:  Alexsandra P Rojas; Kristen Fain; Alan N Peiris
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-11-01

2.  Primary hyperparathyroidism: findings from the retrospective evaluation of cases over a 6-year period from a regional UK centre.

Authors:  Joseph M Pappachan; Mohamed Nabil Elnaggar; Ravinder Sodi; Kahtan Jbeili; Paul R Smith; Ian M Lahart
Journal:  Endocrine       Date:  2018-07-17       Impact factor: 3.633

3.  "Silent" kidney stones in "asymptomatic" primary hyperparathyroidism-a comparison of multidetector computed tomography and ultrasound.

Authors:  Andreas Selberherr; Marcus Hörmann; Gerhard Prager; Philipp Riss; Christian Scheuba; Bruno Niederle
Journal:  Langenbecks Arch Surg       Date:  2016-10-12       Impact factor: 3.445

4.  Diagnosis and treatment of primary hyperparathyroidism with pathological fracture of the limbs: A retrospective observational study.

Authors:  Huijiang Liu; Kai Luo; Shijie Liao; Haijun Tang; Jianming Mo; Tianyu Xie; Chong Li; Boxiang Li; Yun Liu; Xinli Zhan
Journal:  Medicine (Baltimore)       Date:  2022-08-19       Impact factor: 1.817

5.  Limited disease progression in endocrine surgery patients with treatment delays due to COVID-19.

Authors:  Reagan A Collins; Catherine DiGennaro; Toni Beninato; Rajshri M Gartland; Natalia Chaves; Jordan M Broekhuis; Lekha Reddy; Jenna Lee; Angelina Deimiller; Maeve M Alterio; Michael J Campbell; Yeon Joo Lee; Tyler K Khilnani; Latoya A Stewart; Mollie A O'Brien; Miguel Valdivia Y Alvarado; Feibi Zheng; David McAneny; Rachel Liou; Catherine McManus; Sophie Y Dream; Tracy S Wang; Tina W Yen; Amal Alhefdhi; Brendan M Finnerty; Thomas J Fahey; Claire E Graves; Amanda M Laird; Matthew A Nehs; Frederick Thurston Drake; James A Lee; Christopher R McHenry; Benjamin C James; Janice L Pasieka; Jennifer H Kuo; Carrie Cunningham Lubitz
Journal:  Surgery       Date:  2022-08-29       Impact factor: 4.348

6.  Declining Rates of Inpatient Parathyroidectomy for Primary Hyperparathyroidism in the US.

Authors:  Sun Moon Kim; Aimee D Shu; Jin Long; Maria E Montez-Rath; Mary B Leonard; Jeffrey A Norton; Glenn M Chertow
Journal:  PLoS One       Date:  2016-08-16       Impact factor: 3.240

Review 7.  Should Symptoms Be Considered an Indication for Parathyroidectomy in Primary Hyperparathyroidism?

Authors:  Alexandria D McDow; Rebecca S Sippel
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2018-06-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.